Nurr1 repression mediates cardinal features of Parkinson's disease in α-synuclein transgenic mice.
Journal
Human molecular genetics
ISSN: 1460-2083
Titre abrégé: Hum Mol Genet
Pays: England
ID NLM: 9208958
Informations de publication
Date de publication:
28 07 2021
28 07 2021
Historique:
received:
04
03
2021
revised:
17
04
2021
accepted:
19
04
2021
pubmed:
27
4
2021
medline:
8
4
2022
entrez:
26
4
2021
Statut:
ppublish
Résumé
Duplication/triplication mutations of the SNCA locus, encoding alpha-synuclein (ASYN), and loss of function mutations in Nurr1, a nuclear receptor guiding midbrain dopaminergic neuron development, are associated with familial Parkinson's disease (PD). As we age, the expression levels of these two genes in midbrain dopaminergic neurons follow opposite directions and ASYN expression increases while the expression of Nurr1 decreases. We investigated the effect of ASYN and Nurr1 age-related expression alterations in the pathogenesis of PD by coupling Nurr1 hemizygous with ASYN(s) (heterozygote) or ASYN(d) (homozygote) transgenic mice. ASYN(d)/Nurr1+/- (2-hit) mice, contrary to the individual genetic traits, developed phenotypes consistent with dopaminergic dysfunction. Aging '2-hit' mice manifested kyphosis, severe rigid paralysis, L-DOPA responsive movement impairment and cachexia and died prematurely. Pathological abnormalities of phenotypic mice included SN neuron degeneration, extensive neuroinflammation and enhanced ASYN aggregation. Mice with two wt Nurr1 alleles [ASYN(d)/Nurr1+/+] or with reduced ASYN load [ASYN(s)/Nurr1+/-] did not develop the phenotype or pathology. Critically, we found that aging ASYN(d), in contrast to ASYN(s), mice suppress Nurr1-protein levels in a brain region-specific manner, which in addition to Nurr1 hemizygosity is necessary to instigate PD pathogenesis. Our experiments demonstrate that ASYN-dependent PD-related pathophysiology is mediated at least in part by Nurr1 down-regulation.
Identifiants
pubmed: 33902111
pii: 6246271
doi: 10.1093/hmg/ddab118
pmc: PMC8330896
doi:
Substances chimiques
Nr4a2 protein, mouse
0
Nuclear Receptor Subfamily 4, Group A, Member 2
0
alpha-Synuclein
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1469-1483Informations de copyright
© The Author(s) 2021. Published by Oxford University Press.
Références
Science. 2003 Oct 31;302(5646):841
pubmed: 14593171
Cell. 2009 Apr 3;137(1):47-59
pubmed: 19345186
Nature. 1997 Aug 28;388(6645):839-40
pubmed: 9278044
J Comp Neurol. 2006 Jan 20;494(3):495-514
pubmed: 16320253
Behav Genet. 2000 May;30(3):171-82
pubmed: 11105391
Eur J Neurosci. 2019 Feb;49(4):533-560
pubmed: 30552719
Neurobiol Aging. 2010 Dec;31(12):2103-14
pubmed: 19152986
Behav Brain Res. 2003 Jul 14;143(1):95-100
pubmed: 12842300
Mov Disord. 2006 Jul;21(7):906-9
pubmed: 16532445
J Comp Neurol. 2002 Aug 26;450(3):203-14
pubmed: 12209851
J Comp Neurol. 2000 Aug 28;424(3):476-88
pubmed: 10906714
Science. 1997 Jun 27;276(5321):2045-7
pubmed: 9197268
Exp Neurol. 1994 Apr;126(2):195-204
pubmed: 7925820
J Neurosci. 2006 Apr 12;26(15):3942-50
pubmed: 16611810
Acta Neuropathol Commun. 2014 Nov 12;2:156
pubmed: 25387690
Nat Commun. 2013;4:1562
pubmed: 23463005
Mech Ageing Dev. 2009 Apr;130(4):240-7
pubmed: 19150624
Mol Neurodegener. 2009 Jul 24;4:34
pubmed: 19630976
Front Aging Neurosci. 2015 Sep 02;7:168
pubmed: 26388766
J Neurosci. 2012 Jul 4;32(27):9248-64
pubmed: 22764233
J Neurosci. 2010 Mar 3;30(9):3409-18
pubmed: 20203200
Mov Disord. 2006 Nov;21(11):1960-3
pubmed: 16977628
Aging Cell. 2015 Jun;14(3):293-308
pubmed: 25677794
Neurology. 2004 Apr 13;62(7):1231-2
pubmed: 15079038
J Neurochem. 2003 May;85(4):957-68
pubmed: 12716427
Lancet. 2004 Sep 25-Oct 1;364(9440):1167-9
pubmed: 15451224
Neurobiol Aging. 2012 May;33(5):1001.e7-16
pubmed: 21531044
Nat Genet. 2003 Jan;33(1):85-9
pubmed: 12496759
Arch Neurol. 2008 Dec;65(12):1577-81
pubmed: 19064744
Sci Transl Med. 2012 Dec 5;4(163):163ra156
pubmed: 23220632
J Neurochem. 1999 Nov;73(5):2218-21
pubmed: 10537083
Science. 1997 Apr 11;276(5310):248-50
pubmed: 9092472
Neuroreport. 2008 May 28;19(8):867-71
pubmed: 18463503
Mov Disord. 2015 Jul;30(8):1098-106
pubmed: 25753906
Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):4013-8
pubmed: 9520484
Neuron. 2002 May 16;34(4):521-33
pubmed: 12062037
Mol Psychiatry. 2007 Aug;12(8):756-66
pubmed: 17457314
Front Mol Neurosci. 2020 May 12;13:64
pubmed: 32477062
Neurology. 2009 Feb 3;72(5):432-8
pubmed: 19188574
J Neurochem. 2003 May;85(3):622-34
pubmed: 12694388
Proc Natl Acad Sci U S A. 2017 Apr 11;114(15):3999-4004
pubmed: 28348207
Proc Natl Acad Sci U S A. 2015 Jul 14;112(28):8756-61
pubmed: 26124091
PLoS One. 2010 Jul 07;5(7):e11464
pubmed: 20628651
Nat Rev Neurosci. 2011 Jun;12(6):359-66
pubmed: 21587290
Exp Neurol. 2009 Dec;220(2):359-65
pubmed: 19800328
Nat Commun. 2019 Aug 2;10(1):3473
pubmed: 31375685
Brain Res. 1987 Mar 3;405(1):26-38
pubmed: 2882814
Curr Biol. 2012 Sep 11;22(17):R741-52
pubmed: 22975005
Neurobiol Dis. 2007 Jan;25(1):134-49
pubmed: 17055279
Biomolecules. 2015 Oct 16;5(4):2675-700
pubmed: 26501339
Neurosci Lett. 2009 Jun 26;457(2):75-9
pubmed: 19429166